Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Yuval Cohen Ph.D. |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts 02062 United States | |
| Phone | 617-963-0103 |
| Website | corbuspharma.com |
Stock Details
| Ticker Symbol | CRBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595097 |
| CUSIP Number | 21833P103 |
| ISIN Number | US21833P3010 |
| Employer ID | 46-4348039 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
| Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Lindsey Smith | Head of Corporate Communications and Patient Advocacy |
| Christina Bertsch | Head of Human Resources |
| Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 144 | Filing |
| Jun 14, 2024 | 144 | Filing |
| Jun 3, 2024 | 8-K | Current Report |
| May 31, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 20, 2024 | 8-K | Current Report |
| May 9, 2024 | 8-K | Current Report |
| May 8, 2024 | 144 | Filing |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |